This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.

Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter.

Medtronic (MDT) announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping ...

Medtronic (NYSE: MDT) announced today that the FDA approved an early feasibility study to evaluate its Affera system for ...

The study aims to assess the Catheter and Affera system in patients who have ventricular tachycardia (VT) due to scarring ...

The next wave could grow the market further. Medtronic has received Food and Drug Administration approval to study its Affera ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug ...

Affera, a 14-year-old camper in Sarasota, said she grew up watching her dad abuse alcohol. Through camp, she said she has learned that her dad's substance abuse issues are, "not because he doesn't ...

Medtronic plc received U.S. FDA approval to undertake an early feasibility study of its dual-energy Affera cardiac ablation system in sustained ventricular tachycardia. Affera combines both ...

Madi, left, and Affera write letters to addiction at Camp Mariposa in Sarasota, Florida. Katie Kindelan/ABC News In some cases, like Madi's, campers have lost a parent to substance abuse ...

Shares in Boston Scientific (NYSE:BSX) fell more than 1% in premarket trading Friday after analysts at Needham & Co.

Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...